Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060272 | 0.85 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL10079644 | 0.81 | PER2 (0.33) | PIK3CD | |
| SCHEMBL10060276 | 0.81 | PER2 (0.33) | PIK3CD | |
| SCHEMBL11964598 | 0.77 | PER2 (0.32) | PIK3CD | |
| SCHEMBL15468331 | 0.76 | PIK3CD (0.41) | PIK3CDCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL15468335 | 0.68 | PIK3CD (0.34) | PIK3CDCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9251617 | 0.66 | PIK3CD (0.52) | PIK3CDCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL16472435 | 0.66 | PIK3CD (0.52) | PIK3CDCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL18821171 | 0.66 | PIK3CD (0.52) | PIK3CDCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12771380 | 0.64 | PIK3CD (0.38) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | PIK3CD 2589/4885CHRM2 4133/4885CHRM4 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.